Merck & Co., Inc. (NYSE:MRK) is one of the Cheap NYSE Stocks to Buy Now. On December 5, an analyst from Guggenheim raised the ...

Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Merck & Co has a lower P/E than the aggregate P/E of 57.45 of the Pharmaceuticals industry. Ideally, one might believe that ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in. Guggenheim lifted the price target on Merck & Co.

After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax. Late last week, the U.S. Court of ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

Merck & Co., Inc. (MRK) is a leading global healthcare company specializing in the research, development, and distribution of prescription medicines, vaccines, and animal health products. Its ...

But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...